1. Scrip
  2. >>Therapy Areas
  3. >>Immunological

Pfizer's Oral Abroctinib Bests Injectable Dupixent In Atopic Dermatitis Trial

 
• By Jessica Merrill

Only top-line data were released by Pfizer, and the safety of abrocitinib, like other JAK inhibitors, could remain an issue.

Comparison scale
Pfizer says abrocitinib performed better than Dupixent in a Phase III trial • Source: Alamy

Pfizer Inc.'s oral JAK1 inhibitor abrocitinib outperformed Sanofi/Regeneron Pharmaceuticals, Inc.'s blockbuster Dupixent (dupilumab) on efficacy in a head-to-head trial in atopic dermatitis, Pfizer reported on 30 August. The data are the first from a head-to-head trial comparing the two products, which work through different mechanisms of action.

Abrocitinib, which is under review at the US Food and Drug Administration, could be a new competitor in the therapeutic area. It's administered orally, which could be an advantage over Dupixent, which is injected subcutaneously, but Dupixent has a strong foothold in the market and a well characterized safety profile. Dupixent is an IL-4/IL-13 inhibitor that was the first biologic therapy approved for atopic dermatitis by the FDA in 2017

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immunological

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.

EU Approves Tremfya In Third Indication, Ulcerative Colitis

 
• By Sushmita Panda

J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.

More from Therapy Areas

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.

In Brief: Strong OS Results For Immutep’s Eftilagimod/Keytruda Combo In Head And Neck Cancer

 
• By Sushmita Panda

Australian firm's combo of eftilagimod and Keytruda shows 17.6-month median overall survival in first-line HNSCC patients with low PD-L1, raising hopes for potential accelerated approval.